Your browser doesn't support javascript.
loading
Two dose levels of ifosfamide in malignant mesothelioma.
Içli, F; Karaoguz, H; Hastürk, S; Kurt, B; Akbulut, H; Dinçol, D; Demirkazik, A; Cay, F; Akyar, S.
Afiliação
  • Içli F; Ankara University Medical School, Ibn-i Sing Hospital, Medical Oncology Department, Ankara, Turkey.
Lung Cancer ; 15(2): 207-13, 1996 Sep.
Article em En | MEDLINE | ID: mdl-8882987
Thirty-one consecutive patients with histologically proven and symptomatic malignant mesothelioma were treated with two dose levels of ifosfamide. The first group of 15 patients were given 2.3 g/m2/day for 5 days (group A) and the following 16 patients were treated with 1.2 g/m2/day for 5 days of ifosfamide (group B). Treatment cycles were repeated every 3 weeks. While the partial response rate (PR) in group A was 38.5%, it was only 6.25% in group B (P > 0.05). The 95% confidence interval for the difference in PR rates was 3.3-61.2% > The overall survival (OAS) of groups A and B were similar (8 months and 9 months, respectively). Higher Grade 3-4 myelotoxicity was observed in group A when compared to group B (30.8% vs. 18.7%; P > 0.05). In conclusion, a favourable response rate could be achieved in malignant mesothelioma with high dose ifosfamide at the cost of increased toxicity.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antineoplásicos Alquilantes / Ifosfamida / Mesotelioma Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lung Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 1996 Tipo de documento: Article País de afiliação: Turquia
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antineoplásicos Alquilantes / Ifosfamida / Mesotelioma Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lung Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 1996 Tipo de documento: Article País de afiliação: Turquia